Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Operations: 2013-2025

Historic Cash from Operations for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $52.6 million.

  • Amphastar Pharmaceuticals' Cash from Operations fell 12.31% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.3 million, marking a year-over-year decrease of 26.87%. This contributed to the annual value of $213.4 million for FY2024, which is 16.28% up from last year.
  • Amphastar Pharmaceuticals' Cash from Operations amounted to $52.6 million in Q3 2025, which was up 47.74% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Cash from Operations ranged from a high of $69.1 million in Q2 2024 and a low of $2.6 million during Q3 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Cash from Operations averaged around $47.3 million, with its median value being $52.6 million (2025).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Cash from Operations slumped by 91.25% in 2022 and then soared by 1,851.08% in 2023.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Cash from Operations stood at $40.4 million in 2021, then tumbled by 62.35% to $15.2 million in 2022, then skyrocketed by 56.73% to $23.9 million in 2023, then increased by 21.62% to $29.0 million in 2024, then declined by 12.31% to $52.6 million in 2025.
  • Its Cash from Operations stands at $52.6 million for Q3 2025, versus $35.6 million for Q2 2025 and $35.1 million for Q1 2025.